August 5, 2008

BRAFV600E Mutation and Outcome of Patients with Papillary Thyroid Carcinoma: A 15-Year Median Follow-Up Study

RERossella EliseiUniversity of Pisa CUClara UgoliniUniversity of Pisa DVDavid ViolaOspedale Versilia

Key Points

Key points are not available for this paper at this time.

Abstract

In this study the BRAF(V600E) mutation correlated with the worst outcome for PTC patients, who were not only at a higher risk not to be cured but also for death. In particular, the BRAF(V600E) mutation was demonstrated to be a poor prognostic factor independent from other clinicopathological features.

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

Cite This Study

Elisei et al. (Tue,) studied this question.

synapsesocial.com/papers/69dd67987dbdc4ad1440c8ba https://doi.org/https://doi.org/10.1210/jc.2008-0607

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper